Literature DB >> 22322265

Hypoxia signaling during intestinal ischemia and inflammation.

Almut Grenz1, Eric Clambey, Holger K Eltzschig.   

Abstract

PURPOSE OF REVIEW: During critical illness, alterations of intestinal blood supply and inflammatory activation can result in severe intestinal hypoxia (limited oxygen availability). Conditions of hypoxia lead to the activation of a transcriptional program that is under the control of the transcription factor hypoxia-inducible factor (HIF). In many instances, HIF-dependent alterations of gene expression represent endogenous adaptive responses that dampen pathologic inflammation and could be targeted to treat intestinal injury. RECENT
FINDINGS: Post-translational stabilization of the HIF transcription factor and corresponding changes in gene expression are central to the resolution of intestinal injury. Examples for such responses that we discuss in this review include hypoxia-elicited increases in extracellular adenosine production and signaling, particularly through the A2B adenosine receptor, and intestinal protection provided by hypoxia-inducible netrin-1.
SUMMARY: The present review focuses on HIF-elicited anti-inflammatory pathways that result in intestinal protection during critical illness. Many of these pathways represent novel therapeutic targets for attenuating multiorgan failure and critical illness. Whereas these therapeutic approaches are currently being investigated in cell culture models or in genetic mouse models, we are optimistic that at least some of these novel targets can be translated from bench to bedside in the near future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22322265      PMCID: PMC3855266          DOI: 10.1097/MCC.0b013e3283514bd0

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  95 in total

1.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

2.  Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor.

Authors:  Melanie L Hart; Almut Grenz; Iris C Gorzolla; Jens Schittenhelm; Julee H Dalton; Holger K Eltzschig
Journal:  J Immunol       Date:  2011-02-28       Impact factor: 5.422

3.  Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation.

Authors:  Ann-Kathrin Riegel; Marion Faigle; Stephanie Zug; Peter Rosenberger; Bernard Robaye; Jean-Marie Boeynaems; Marco Idzko; Holger K Eltzschig
Journal:  Blood       Date:  2010-12-20       Impact factor: 22.113

4.  Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia.

Authors:  Almut Grenz; Hua Zhang; Tobias Eckle; Michel Mittelbronn; Manfred Wehrmann; Christoph Köhle; Doris Kloor; Linda F Thompson; Hartmut Osswald; Holger K Eltzschig
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

5.  HIF-dependent induction of adenosine A2B receptor in hypoxia.

Authors:  Tianqing Kong; Karen A Westerman; Marion Faigle; Holger K Eltzschig; Sean P Colgan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

Review 6.  Hypoxia and gastrointestinal disease.

Authors:  Cormac T Taylor; Sean P Colgan
Journal:  J Mol Med (Berl)       Date:  2007-11-20       Impact factor: 4.599

7.  Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.

Authors:  Jörg Reutershan; Irene Vollmer; Stefanie Stark; Rosalyn Wagner; Kristian-Christos Ngamsri; Holger K Eltzschig
Journal:  FASEB J       Date:  2008-10-06       Impact factor: 5.191

Review 8.  Oxygen sensors at the crossroad of metabolism.

Authors:  Julián Aragonés; Peter Fraisl; Myriam Baes; Peter Carmeliet
Journal:  Cell Metab       Date:  2009-01-07       Impact factor: 27.287

9.  HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia.

Authors:  Holger K Eltzschig; Parween Abdulla; Edgar Hoffman; Kathryn E Hamilton; Dionne Daniels; Caroline Schönfeld; Michaela Löffler; German Reyes; Michael Duszenko; Jorn Karhausen; Andreas Robinson; Karen A Westerman; Imogen R Coe; Sean P Colgan
Journal:  J Exp Med       Date:  2005-12-05       Impact factor: 14.307

10.  Physiological roles for ecto-5'-nucleotidase (CD73).

Authors:  Sean P Colgan; Holger K Eltzschig; Tobias Eckle; Linda F Thompson
Journal:  Purinergic Signal       Date:  2006-06-01       Impact factor: 3.765

View more
  25 in total

Review 1.  Attenuating myocardial ischemia by targeting A2B adenosine receptors.

Authors:  Holger K Eltzschig; Stephanie K Bonney; Tobias Eckle
Journal:  Trends Mol Med       Date:  2013-03-26       Impact factor: 11.951

Review 2.  Cardiovascular Alterations and Multiorgan Dysfunction After Birth Asphyxia.

Authors:  Graeme R Polglase; Tracey Ong; Noah H Hillman
Journal:  Clin Perinatol       Date:  2016-06-22       Impact factor: 3.430

3.  Central role for endothelial human deneddylase-1/SENP8 in fine-tuning the vascular inflammatory response.

Authors:  Stefan F Ehrentraut; Douglas J Kominsky; Louise E Glover; Eric L Campbell; Caleb J Kelly; Brittelle E Bowers; Amanda J Bayless; Sean P Colgan
Journal:  J Immunol       Date:  2012-12-03       Impact factor: 5.422

4.  Signaling through hepatocellular A2B adenosine receptors dampens ischemia and reperfusion injury of the liver.

Authors:  Michael A Zimmerman; Almut Grenz; Eunyoung Tak; Maria Kaplan; Douglas Ridyard; Kelley S Brodsky; Mercedes Susan Mandell; Igal Kam; Holger K Eltzschig
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-28       Impact factor: 11.205

5.  Hemorrhagic shock-induced cerebral bioenergetic imbalance is corrected by pharmacologic treatment with EF24 in a rat model.

Authors:  Geeta Rao; Jun Xie; Andria Hedrick; Vibhudutta Awasthi
Journal:  Neuropharmacology       Date:  2015-07-29       Impact factor: 5.250

6.  CD73-dependent generation of adenosine and endothelial Adora2b signaling attenuate diabetic nephropathy.

Authors:  Eunyoung Tak; Douglas Ridyard; Jae-Hwan Kim; Michael Zimmerman; Tilmann Werner; Xiaoxin X Wang; Uladzimir Shabeka; Seong-Wook Seo; Uwe Christians; Jost Klawitter; Radu Moldovan; Gabriela Garcia; Moshe Levi; Volker Haase; Katya Ravid; Holger K Eltzschig; Almut Grenz
Journal:  J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 10.121

7.  Global hypoxia-ischemia induced inflammation and structural changes in the preterm ovine gut which were not ameliorated by mesenchymal stem cell treatment.

Authors:  Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs
Journal:  Mol Med       Date:  2016-04-14       Impact factor: 6.354

Review 8.  Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease.

Authors:  Jens M Poth; Kelley Brodsky; Heidi Ehrentraut; Almut Grenz; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2012-12-21       Impact factor: 4.599

9.  Netrin-1 is highly expressed and required in inflammatory infiltrates in wear particle-induced osteolysis.

Authors:  Aránzazu Mediero; Bhama Ramkhelawon; Tuere Wilder; P Edward Purdue; Steven R Goldring; M Zahidunnabi Dewan; Cynthia Loomis; Kathryn J Moore; Bruce N Cronstein
Journal:  Ann Rheum Dis       Date:  2015-10-09       Impact factor: 19.103

10.  Protective role for netrin-1 during diabetic nephropathy.

Authors:  Eunyoung Tak; Douglas Ridyard; Alexander Badulak; Antasia Giebler; Uladzimir Shabeka; Tilmann Werner; Eric Clambey; Radu Moldovan; Michael A Zimmerman; Holger K Eltzschig; Almut Grenz
Journal:  J Mol Med (Berl)       Date:  2013-05-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.